socalTECH

MARCH 29, 2021

San Diego-based Fortis Therapeutics, a biotechnology startup developing treatments for late-stage prostate cancer and multiple myeloma, has raised $40M in a Series A financing, the company said on Monday.

Avalon 113

Avalon San Diego Research Funding 113

socalTECH

JULY 17, 2014

The latest venture capital totals from the PricewaterhouseCoopers/National Venture Capital Association''s MoneyTree Report was released this evening, tallying up $761.12M in investments in Q2 of 2014 in Southern California, up from Q2 of 2013, when $616.83M was invested in the region. Nationally, there was $13.0 READ MORE>>.

Southern California 240

Southern California El Segundo Culver City Orange County 240

socalTECH

AUGUST 18, 2016

San Diego-based biopharmaceuticals developer Avelas Biosciences has raised $20M in a Series C funding, according to the company. and laos included Ervington Investments Limited and Alexandria Venture Investments plus Avalon Ventures, Bregua Corporation, and WuXi Healthcare Ventures.

Avalon 100

Avalon San Diego Invest Funding 100

socalTECH

SEPTEMBER 10, 2014

San Diego-based Avelas Biosciences , which is developing cell penetrating peptides to light up cancerous tissue in patients during surgery, has raised $7.4M The second tranche of the company''s Series B came from investors Avalon Ventures, Torrey Pines Investment and WuXi PharmaTech Investments. in a Series B funding.

Avalon 147

Avalon San Diego Venture Capital Research 147

socalTECH

JANUARY 9, 2014

The company said the funding came from Avalon Ventures, and also included Torrey Pines Investment, WuXi AppTec, and an additional, un-named investor. Avelas Biosciences is developing a flourecent peptide which helps surgeons highlight cancer cells during surgery, specifically for breast cancer. READ MORE>>.

Avalon 138

Avalon San Diego Funding Capital 138

socalTECH

JANUARY 26, 2017

San Diego-based AnaptysBio , which develops antibodies for treating inflammation, has raised $75.0M AnaptysBio is backed by Frazier Healthcare, Novo A/S, Avalon Ventures, Alloy Ventures, Biotechnology Value Fund, HBM Healthcare Investments, and others. in its IPO, and closed up slightly in its first day of trading on Thursday.

Avalon 100

Avalon San Diego Pricing Invest 100

socalTECH

JANUARY 17, 2017

San Diego-based AnaptysBio , which develops antibodies for treating inflammation, has set its estimated IPO pricing range, saying on Tuesday that it expects to price its IPO at between $14.00 AnaptysBio is backed by Frazier Healthcare, Novo A/S, Avalon Ventures, Alloy Ventures, Biotechnology Value Fund, HBM Healthcare Investments, and others.

Pricing 100

Pricing Avalon Southern California Venice 100

socalTECH

JULY 18, 2013

in venture capital investments in Q2 2013 across Southern California, spread across 80 deals. Those numbers reflected a drop from Q2 of last year, when there was $868.98M in investments across 97 deals. However, venture dollars invested were above Q1, when Southern California saw $569.1M in investments across 90 deals.

Southern California 187

Southern California Venture Capital Tech Coast Angels Capital 187

socalTECH

JUNE 4, 2012

San Diego-based Awarepoint , which develops real-time, location systems used for tracking patents and assets in a healthcare environment, said today that it has raised $14M in an additional financing round. of the new investment round, which the company said will go to expand its services, client management, and manufacturing capabilities.

Avalon 140

Avalon San Diego Patents Invest 140

Xconomy

AUGUST 17, 2016

Pharmstandard International, the Luxembourg-based investment arm of the Russian pharmaceutical giant Pharmstandard (and a first-time investor in Avelas), led the round. It was joined by two other new backers, Ervington Investments and Alexandria Venture Investments, and previous investors WuXi Healthcare Ventures, Bregua Corp.,

Avalon 40

Avalon San Diego Study Invest 40

socalTECH

JULY 12, 2010

The firm said the contract covers developing antibodies that could be used by the military in antibody-based biosensors, including those that can detect bioterrorist threats. Anaptys is backed by Alloy Ventures, Avalon Ventures, Frazier Healthcare Ventures, Novo A/S, Numenor Ventures, and WS Investments.

Outsource Development 140

Outsource Development Avalon San Diego Research 140

Xconomy

JULY 19, 2016

Existing investors Avalon Ventures and Correlation Ventures joined in the round. The San Diego firms have invested $6 million since 2014, when Synthorx was founded , CEO Court Turner said yesterday. The initial goal at Synthorx, Turner said, was to use the techniques developed in Romesberg’s lab to insert synthetic DNA into E.

San Diego 40

San Diego Avalon Research Examples 40

Xconomy

AUGUST 30, 2017

Investment in experimental drugs for hearing loss, long an untapped field in the pharmaceutical industry, may be picking up, but drugs that actually help with these disorders remain elusive.

San Diego 59

San Diego Invest Help Develop 59

Xconomy

JANUARY 26, 2017

biotech company to go public this year, raising $75 million in an IPO intended to finance development of antibody-based drugs for inflammatory disorders. Stockholders who had invested in the. AnaptysBio is the first U.S. Anaptys also sold 1 million more shares that it had initially planned.

Marketing 40

Marketing San Diego Invest Help 40